-- Peer-reviewed publication in Alzheimer's & Dementia: Translational Research & Clinical Interventions validates potential of drug discovery platform and ability to study early stages of disease pathology --
Hesperos Inc., pioneers of the Human-on-a-Chip in vitro system, today announced a new peer-reviewed publication that describes how the companys functional Human-on-a-Chip system can be used as a drug discovery platform to identify therapeutic interventions targeting the preclinical stages of Alzheimers disease (AD) and mild cognitive impairment (MCI). The manuscript, titled "A human induced pluripotent stem cell-derived cortical neuron human-on-a-chip system to study A42 and tau-induced pathophysiological effects on long-term potentiation," was published this week in Alzheimer's & Dementia: Translational Research & Clinical Interventions. The work was conducted in collaboration with the University of Central Florida and with David G. Morgan, Ph.D., Professor of Translational Neuroscience at Michigan State University, and expert in AD pathology.
To date, more than 100 potential therapeutics in development for AD have been abandoned or failed during clinical trials. These therapeutics relied on research conducted in preclinical animal studies, which often are unable to accurately capture the full spectrum of the human disease phenotype, including differences in drug metabolism and excretion between humans and animals. Therefore, there is a need for human models, especially those that accurately recapitulate the functional impairments during the preclinical phases of AD and MCI.
"Hesperos offers a breakthrough technology that provides a human cell-based assay based on cognitive function metrics to evaluate drugs designed to restore cognition at early stages of the Alzheimers continuum," said Dr. Morgan. "This system can serve as a novel drug discovery platform to identify compounds that rescue or alleviate the initial neuronal deficits caused by A1-42 and/or tau oligomers, which is a main focus of clinical trials."
In 2018, Hesperos received a Phase I Small Business Innovation Research (SBIR) grant from the National Institute on Aging (NIA) division within the US National Institutes of Health (NIH) to help create a new multi-organ human-on-a-chip model for testing AD drugs. Research conducted under this grant included a study to assess therapeutic interventions based on functional changes in neurons, not neuronal death.
In the recent Alzheimer's & Dementia publication, Hesperos describes its in vitro human induced pluripotent stem cell (iPSC)-derived cortical neuron human-on-a-chip system for the evaluation of neuron morphology and function after exposure to toxic A and tau oligomers as well as brain extracts from AD transgenic mouse models.
"Researchers are now focusing on biomarker development and therapeutic intervention before symptoms arise in AD and MCI," said James Hickman, Ph.D., Chief Scientist at Hesperos and Professor at the University of Central Florida. "By studying functional disruption without extensive cell loss, we now have a screening methodology for drugs that could potentially evaluate therapeutic efficacy even before the neurodegeneration in MCI and AD occurs."
The researchers found that compared to controls, treatment with toxic A and tau oligomers or brain extracts on the iPSC cortical neurons significantly impaired information processing as demonstrated by reduction in high-frequency stimulation-induced long-term potentiation (LTP), a process that is thought to underlie memory formation and learning. Additionally, oligomer and brain extract exposure led to dysfunction in iPSC cortical neuron electrophysiological activity, including decreases in ion current and action potential firing.
While exposure to the toxic oligomers and brain extracts caused morphological defects in the iPSC cortical neurons, there was no significant loss in cell viability.
"Clinical success for AD therapies has been challenging since preclinical animal studies often do not translate to humans," said Michael L. Shuler, Ph.D., Chief Executive Officer of Hesperos. "With our recent study, we are now one step closer in developing an AD multi-organ model to better evaluate drug metabolism in the liver, penetration through the blood-brain barrier and the effects on neuronal cells."
Story continues
About Alzheimers Disease/Preclinical Stage AD
AD is a progressive disease that is characterized by memory loss and deterioration of cognitive function. Preclinical AD is the first stage of the disease, and it begins long before any symptoms become apparent. It is thought that symptoms do not manifest until there is a significant death of neuronal cells, which is caused by the aggregation of toxic amyloid beta (A) and tau oligomers, typically during the earliest stages of the disease. Unfortunately, treatment after the diagnosis of MCI may be too late to reverse or modify disease progression.
To read the full manuscript, please visit https://alz-journals.onlinelibrary.wiley.com/doi/full/10.1002/trc2.12029.
About Hesperos
Hesperos, Inc. is a leading provider of Human-on-a-Chip microfluidic systems to characterize an individuals biology. Founders Michael L. Shuler and James J. Hickman have been at the forefront of every major scientific discovery in this realm, from individual organ-on-a-chip constructs to fully functional, interconnected multi-organ systems. With a mission to revolutionize toxicology testing as well as efficacy evaluation for drug discovery, the company has created pumpless platforms with serum-free cellular mediums that allow multi-organ system communication and integrated computational PKPD modeling of live physiological responses utilizing functional readouts from neurons, cardiac, muscle, barrier tissues and neuromuscular junctions as well as responses from liver, pancreas and barrier tissues. Created from human stem cells, the fully human systems are the first in vitro solutions to accurately predict in vivo functions without the use of animal models. More information is available at http://www.hesperosinc.com.
Hesperos and Human-on-a-Chip are trademarks of Hesperos Inc. All other brands may be trademarks of their respective holders.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200529005128/en/
Contacts
Michelle LinnBioscribe774-696-3803michelle@bioscribe.com
Original post:
Hesperos Human-on-a-Chip System Used to Model Preclinical Stages of Alzheimers Disease and Mild Cognitive Impairment - Yahoo Finance
- Organoids: science fiction or the future of pre-clinical studies? - Lexology - October 13th, 2022
- Researchers develop method to study brain connectivity, functionality - Florida Hospital News and Healthcare Report - South Florida Hospital News - October 13th, 2022
- A win for stem cells | Washington Examiner - October 4th, 2022
- TransMedia Group to Illumine Impressive Neuro Healing Results Achieved by Raymond Cralle, a Pioneer in Hyperbaric Oxygen Therapy and a Florida... - September 16th, 2022
- Sure Signs You Have Non-Hodgkin's Lymphoma Eat This Not That - Eat This, Not That - August 22nd, 2022
- New treatment changing outlook for those with blood cancers - WBAL TV Baltimore - July 19th, 2022
- Engineering Graduate Fellows Get Hands-on Experience with National Industry Leaders - UCF - July 11th, 2022
- New Alzheimer's Treatment on Horizon as Dementia Reversed for First Time in Dogs - StreetInsider.com - June 22nd, 2022
- Life Cycle of a Moss - Infographic - STEM Lounge - June 13th, 2022
- Miller School Researchers on the Trail to Unraveling Long COVID-19 - Florida Hospital News and Healthcare Report - South Florida Hospital News - June 4th, 2022
- American Academy of Stem Cell Physicians is Proud to Add to the Speaker Roster, Dr. Scheffer Tseng, Acclaimed Opthamologist and Founder of Bio-Tissue... - May 15th, 2022
- 'Doctors gave me six months to live in 2016 but I continue to defy every expectation' - Wales Online - May 2nd, 2022
- Revolutionary Oxygen Healing Therapy Now Available in Florida - Digital Journal - March 25th, 2022
- Global Mesenchymal Stem Cells Market Analysis, Opportunities, Trend and Forecast To 2029 Discovery Sports Media - Discovery Sports Media - January 20th, 2022
- EDUCATION SPOTLIGHT: Florida Tech Highlights Work Done During 2021 as We Enter the New Year - SpaceCoastDaily.com - January 5th, 2022
- Roundtable Discussion: Shain Looks at the Role of Transplant Eligibility in Patients With Newly Diagnosed Multiple Myeloma - Targeted Oncology - November 8th, 2021
- ALS and dementia attacked by an RNA-hunting compound that recruits cell's own virus fighter - EurekAlert - October 28th, 2021
- Brainstorm Cell, (BCLI) falls 0.65% in Active Trading on October 25 - Equities.com - October 28th, 2021
- Global Mesenchymal Stem Cells Market Prospects, Upcoming Trends and Competitive Outlook till 2028 | Lonza, Thermo Fisher, Bio-Techne, ATCC,... - October 28th, 2021
- Faster healing of wounds can decrease pain and suffering and save lives - WWNY - October 5th, 2021
- US FDA Approves Kite's Tecartus as the First and Only Car T for Adults With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia | DNA RNA and... - October 5th, 2021
- Times really up! FDA authority to crack down on regenerative medicines upheld as grace period ends - JD Supra - July 21st, 2021
- Animal Stem Cell Therapy Market Size, Industry Analysis, Growth Factors, Trends, and Regional Forecast to 2027 - The Courier - March 11th, 2021
- An 8-year-olds search for bone marrow match in battle with leukemia comes to North Texas - The Dallas Morning News - March 11th, 2021
- Eirion Therapeutics, Inc. Closes $40 Million Series A Investment and Licensing Deal with Shanghai Haohai Biological Technology Ltd. - PRNewswire - March 11th, 2021
- How soon will COVID-19 vaccines return life to normal? - Science Magazine - February 16th, 2021
- Keep it Flowing: Combating COVID-19 Blood Shortages in Cancer Treatment - Curetoday.com - February 16th, 2021
- FL Doctors Make Breakthrough Using Stem Cells to Treat ... - February 2nd, 2021
- This Guy Injected His Dick With Stem Cells to Try to Make ... - February 2nd, 2021
- 10 Best Stem Cell Beauty Products On The Market Today - February 2nd, 2021
- HealthLynked's The Future of Healthcare Summit Brings Healthcare Experts and Technology Innovators from Around the World to Naples, Florida -... - February 2nd, 2021
- SpaceX Cargo Dragon Returning To Earth; First U.S. Commercial Cargo Craft To Return From ISS - Science Times - January 8th, 2021
- Buoyed by study, scientists increasingly hopeful first two COVID-19 vaccines effective against new strains - The Boston Globe - January 8th, 2021
- Flavors added to vaping devices damage the heart, vanilla custard the most toxic of all - Study Finds - December 23rd, 2020
- Flavours added to vaping devices can damage the heart: Study - Sify News - December 12th, 2020
- Jabbed for a good cause: Hundreds already getting COVID-19 shots as part of clinical trial - The West Volusia Beacon - August 29th, 2020
- Hesperos demonstrates innovative Human-on-a-Chip approach to modeling innate immune system response following tissue damage and acute inflammation -... - June 8th, 2020
- Can genetics explain the degrees of misery inflicted by the coronavirus? - Genetic Literacy Project - April 21st, 2020
- Beating cancer by taking the unbeaten path | ASU Now: Access, Excellence, Impact - ASU Now - April 9th, 2020
- Reviewing CRYO-CELL International (OTCMKTS:CCEL) and Harsco (OTCMKTS:HSC) - Redmond Register - March 26th, 2020
- Head to Head Analysis: Harsco (NYSE:HSC) & CRYO-CELL International (NYSE:CCEL) - Redmond Register - March 24th, 2020
- Reviewing Harsco (NYSE:HSC) and CRYO-CELL International (NYSE:CCEL) - Redmond Register - March 12th, 2020
- Data On Enlivex's Allocetra-OTS Immunotherapy for Peritoneal Solid Tumors and for Prevention of GvHD Selected for Presentation at the Transplantation... - February 24th, 2020
- Consistent Outcomes Using Ryoncil as First-Line Treatment or Salvage Therapy in 309 Children With Steroid-Refractory Acute GVHD - BioSpace - February 24th, 2020
- NASA to send equipment to International Space Station to research Improving Shoes, Showers, 3D Printing - Clarksville Online - February 24th, 2020
- Here are all the science projects that SpaceX will deliver to the ISS - Digital Trends - February 24th, 2020
- 34 years with a new heart and counting - MDJOnline.com - February 24th, 2020
- 'Florida cold' and the semi-glamorous world of work trips - CT Insider - February 19th, 2020
- 34 Years with a New Heart and Counting | 90.1 FM WABE - WABE 90.1 FM - February 19th, 2020
- Study shows how a tiny and strange marine animal produces unlimited eggs and sperm over its lifetime - National Institutes of Health - February 16th, 2020
- Research - Florida Stem Cell Research - January 3rd, 2020
- Florida Stem Cell Treatment Center - January 3rd, 2020
- Advances In Treatment Of Soft Tissue Injuries (Video) - South Florida Reporter - January 3rd, 2020
- Explained: What is the water crisis Southwest Florida is battling? - Wink News - December 24th, 2019
- Mum shares heartbreaking photo of toddler sobbing through gruelling cancer treatment - The Sun - December 1st, 2019
- World AIDS Day 2019: Theme, History and Facts about HIV and AIDS - Newsweek - December 1st, 2019
- Tulane team researching ways to end opioid addiction - News from Tulane - November 24th, 2019
- Improve global wellbeing with a degree in public health - Study International News - November 12th, 2019
- Fate Therapeutics Announces Six Presentations at the 2019 ASH Annual Meeting - GlobeNewswire - November 12th, 2019
- Reviewing US Stem Cell (OTCMKTS:USRM) and Auxly Cannabis Group (OTCMKTS:CBWTF) - Riverton Roll - November 12th, 2019
- Bloomington Vet Joins Study For Stem Cell Therapy To Treat Dogs With Arthritis - WGLT News - October 24th, 2019
- Brooks Koepka Withdraws in Korea After Reaggravating Knee Injury - Golf Channel - October 24th, 2019
- Walking in His Shoes - Curetoday.com - October 5th, 2019
- The Real Problem With Beef - The New York Times - October 2nd, 2019
- Stem Cell Treatment Clinic St. Augustine - Florida Stem Cell - March 17th, 2019
- Stem Cell Questions - Florida Stem Cell - FAQs - February 2nd, 2019
- Stem Cell Procedure for Erectile Dysfunction - January 26th, 2019
- Stuart Florida Stem Cells | NovaGenix - January 18th, 2019
- Stem Cell Hair Treatment for Hair Loss | Stem Cell Hair Growth - January 3rd, 2019
- South Florida Stem Cell Center | Melvin M. Propis, M.D. - December 11th, 2018
- Florida Stem Cell Treatments - Regenerative Orthopedic ... - December 11th, 2018
- Florida - Stem Cells Transplant Institute - July 24th, 2018
- FDA: Florida Stem Cell Clinic Violates Law | Health News ... - October 18th, 2017
- Stem cell research | UF Health, University of Florida Health - October 18th, 2017
- FDA: Serious Problems at Florida Stem Cell Clinic - WebMD - August 29th, 2017
- FDA Cracks Down On Stem-Cell Clinics Selling Unapproved Treatments - KRCB - August 29th, 2017
- US FDA steps up scrutiny of stem cell therapies - Reuters - August 29th, 2017
- Paralyzed After Pool Accident, Student Heads Back To College - News Talk Florida - August 29th, 2017
- SpaceX to Launch NASA Cargo, Try Rocket Landing Today: Watch It Live - Space.com - August 16th, 2017
- Dragon Splashes Down to Complete Resupply Mission - Space Daily - July 7th, 2017